Media & Press relations

Swipe for more

• September 04, 2025

  First-Half 2025 Financial Results

  Consolidated sales amounted to €2,044 million in the first-half of 2025 from €1,902 million in the prior year period, a +9.4% like-for-like growth.

  Read more
  

• August 26, 2025

  OhioHealth Partners with bioMérieux as Newest Global Antimicrobial Stewardship Center of Excellence 

  OhioHealth joins bioMérieux’s AMS Centers of Excellence, advancing diagnostics to fight antimicrobial resistance and improve patient outcomes.

  Read more
  

• August 18, 2025

  bioMérieux receives U.S. 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini

  bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the addition of Anterior Nasal Swab (ANS) as a validated specimen type for this panel, specifically for use with the respiratory test menu.

  Read more